Stock POLYMED POLY MEDICURE LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Poly Medicure Limited NSE India S.E.

Equities

POLYMED

INE205C01021

Market Closed - NSE India S.E.
Other stock markets
 05:19:11 14/05/2024 pm IST 		5-day change 1st Jan Change
1,680 INR +1.29% Intraday chart for Poly Medicure Limited +2.72% +12.79%
02/02 Transcript : Poly Medicure Limited, Q3 2024 Earnings Call, Feb 02, 2024
31/01 Poly Medicure Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The company's profit outlook over the next few years is a strong asset.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • With an expected P/E ratio at 63.13 and 48.98 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company appears highly valued given the size of its balance sheet.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
POLY MEDICURE LIMITED Stock Poly Medicure Limited
+12.79% 190.84Cr -
ABBOTT LABORATORIES Stock Abbott Laboratories
-6.00% 18TCr
C+
MEDTRONIC PLC Stock Medtronic plc
+1.61% 11TCr
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-3.80% 6.85TCr
A
DEXCOM, INC. Stock DexCom, Inc.
+0.74% 4.97TCr
B-
CENCORA, INC. Stock Cencora, Inc.
+7.71% 4.45TCr
B-
HOYA CORPORATION Stock Hoya Corporation
+2.33% 4.07TCr
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+22.34% 3.12TCr
B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+0.89% 2.61TCr
A-
TERUMO CORPORATION Stock Terumo Corporation
+15.30% 2.53TCr
A-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. POLYMED Stock
  4. POLYMED Stock
  5. Ratings Poly Medicure Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW